Malaria Vaccine

About VLP Biotech

VLP Biotech is a private, preclinical-stage biotech firm specializing in vaccine development for infectious diseases using its proprietary recombinant protein platform. The company operates a service-based model for custom antibody production while advancing its own vaccine candidates through early-stage government-funded grants. With a lean structure, it has secured non-dilutive funding from entities like Leidos and the U.S. government's SBIR/STTR programs to fuel its R&D efforts. Its strategy combines contract services with internal pipeline development to address significant unmet medical needs.

About Artificial Cell Technologies

Artificial Cell Technologies is pioneering a novel, fully synthetic vaccine manufacturing platform using Layer-by-Layer (LbL) polypeptide nanofilms. This technology aims to produce temperature-stable, multi-valent vaccines rapidly and at low cost, enabling decentralized production closer to patient populations. The company's initial pipeline targets Respiratory Syncytial Virus (RSV) and malaria, with a malaria vaccine candidate historically noted as preparing for Phase 1 trials. ACT's approach seeks to disrupt traditional vaccine supply chains, particularly for the developing world.

About VLP Therapeutics

VLP Therapeutics is a clinical-stage biotech advancing a novel vaccine platform centered on self-amplifying RNA (saRNA) with modified nucleosides, such as 5-methylcytidine, to improve safety and immunogenicity. The company has a diversified pipeline including COVID-19, malaria, and dengue vaccines, as well as cancer immunotherapies, supported by partnerships and non-dilutive funding from entities like the Gates Foundation. With operations in the US and Japan, VLPT is positioning itself as a player in the next wave of mRNA and replicon vaccine technology, aiming for broader and more durable immune responses.

Therapeutic Areas

Other Malaria Drugs